Tokyo – The rollout of recently approved breast cancer and diabetes treatments from international pharmaceutical companies has faced significant delays in Japan, as ongoing negotiations over pricing persist, underscoring concerns among foreign drugmakers about the country’s stringent state-regulated pricing framework.
Also Read
- Khartoum Residents Reclaim Cinema with Open‑Air Screenings Amid War
- Ossoff’s Integrity and Collins’ Extremes: A Critical Look at Georgia’s Senate Race
- Meghan Markle’s casting in The Gentlemen reportedly withdrawn after UK backlash
- Reddit vs. Rigetti Computing: Evaluating High-Growth Investments for 2026